Evaluation of the prognosis in patients with small-cell lung cancer treated by chemotherapy using tumor shrinkage rate-based radiomics

doi:10.1186/s40001-024-02001-4

科研成果详情

题名	Evaluation of the prognosis in patients with small-cell lung cancer treated by chemotherapy using tumor shrinkage rate-based radiomics
作者	Yuchen Zhou 1; Zhonghan Wu2,3; Haowen Wang 4; Ke Zhang2; Hua Chen 2; Siyu Zhu2; Andriamifahimanjaka Sitrakiniaina 2; Yanting Wu 5; Shaopeng Yang3; Xiaobo Sun 6; Wenfeng Li7; Xiaoming Lin8; Jingjing Jin9
发表日期	2024-08-02
发表期刊	European journal of medical research 影响因子和分区
语种	英语
原始文献类型	Journal Article
关键词	Chemotherapy Prognosis Radiomics Small-cell lung cancer Tumor shrinkage rate
其他关键词	METASTATIC COLORECTAL-CANCER ; FOLFIRI PLUS BEVACIZUMAB ; 1ST-LINE CHEMOTHERAPY ; OPEN-LABEL ; SURVIVAL ; SIZE ; CARCINOMA ; CETUXIMAB ; PROGRESSION ; TOMOGRAPHY
摘要	Small-cell lung cancer (SCLC) is a leading cause of cancer-related death. However, the prognostic value of the tumor shrinkage rate (TSR) after chemotherapy for SCLC is still unknown., We performed a retrospective analysis of 235 patients with SCLC. The TSR cutoff was determined based on receiver-operating characteristic curve analysis. The associations of TSR with progression-free survival (PFS) and overall survival (OS) were assessed using univariate and multivariate Cox proportional hazards models. Survival curves were obtained by the Kaplan-Meier method and compared using the log-rank test. Recurrence patterns after first-line treatment were summarized in a pie chart. A nomogram was constructed to validate the predictive role of the TSR in SCLC., The TSR cutoff was identified to be - 6.6%. Median PFS and OS were longer in the group with a TSR < -6.6% than in the group with a TSR ≥ - 6.6%. PFS and OS were also longer in patients with extensive SCLC when the TSR was < - 6.6% than when it was > - 6.6%. Brain metastasis-free survival was better in the group with a TSR < - 6.6%. There was a significant positive correlation between TSR and PFS. Furthermore, univariate and multivariate regression analyses showed that the TSR, patient age, and previous radiotherapy were independent prognostic factors for OS while TSR and M stage were independent prognostic factors for PFS., The TSR may prove to be a good indicator of OS and PFS in patients receiving chemotherapy-based first-line treatment for SCLC.
资助项目	Innovative Research Group Project of the National Natural Science Foundation of China[81871966];Natural Science Foundation of Zhejiang Province[LY15H160062]
出版者	BMC
ISSN	0949-2321
EISSN	2047-783X
卷号	29 期号:1
DOI	10.1186/s40001-024-02001-4
页数	14
WOS类目	Medicine, Research & Experimental
WOS研究方向	Research & Experimental Medicine
WOS记录号	WOS:001283380500004
收录类别	PUBMED ; SCIE ; SCOPUS
URL	查看原文
PubMed ID	39095855
SCOPUSEID	2-s2.0-85200529150
通讯作者地址	[Lin, Xiaoming]Wenzhou Med Univ, Affiliated Hosp 1, Dept Thorac Surg, Wenzhou, Peoples R China. ; [Jin, Jingjing]Wenzhou Med Univ, Inst Mol Virol & Immunol, Sch Basic Med Sci, Dept Microbiol & Immunol, Wenzhou, Peoples R China.
Scopus学科分类	Medicine (all)
引用统计
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/217115
专题	附属第一医院基础医学院（机能实验教学中心）第一临床医学院（信息与工程学院）、附属第一医院附属第一医院_心胸外科基础医学院（机能实验教学中心）_病原生物学与免疫学系
作者单位	1.Department of Thoracic Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.; 2.Department of Microbiology and Immunology, Institute of Molecular Virology and Immunology, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, China.; 3.School of the First Clinical College, Wenzhou Medical University, Wenzhou, China.; 4.Department of Interventional Medicine, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China.; 5.Jiaxing Maternal and Child Health Hospital, Jiaxing, China.; 6.Department of Laboratory Diagnosis, Changhai Hospital, Navy Military University, Shanghai, China.; 7.Department of Chemoradiation Oncology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.; 8.Department of Thoracic Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. sheermanlin@126.com.; 9.Department of Microbiology and Immunology, Institute of Molecular Virology and Immunology, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, China. AshleyJin0831@163.com.
第一作者单位	附属第一医院; 第一临床医学院（信息与工程学院）、附属第一医院; 心胸外科
通讯作者单位	附属第一医院; 心胸外科; 基础医学院（机能实验教学中心）; 病原生物学与免疫学系
第一作者的第一单位	附属第一医院
推荐引用方式 GB/T 7714	Yuchen Zhou,Zhonghan Wu,Haowen Wang,et al. Evaluation of the prognosis in patients with small-cell lung cancer treated by chemotherapy using tumor shrinkage rate-based radiomics[J]. European journal of medical research,2024,29(1).
APA	Yuchen Zhou., Zhonghan Wu., Haowen Wang., Ke Zhang., Hua Chen., ... & Jingjing Jin. (2024). Evaluation of the prognosis in patients with small-cell lung cancer treated by chemotherapy using tumor shrinkage rate-based radiomics. European journal of medical research, 29(1).
MLA	Yuchen Zhou,et al."Evaluation of the prognosis in patients with small-cell lung cancer treated by chemotherapy using tumor shrinkage rate-based radiomics".European journal of medical research 29.1(2024).